Cai, Rong
Xi, Xiaoyu
Huang, Yuankai
Article History
Received: 11 January 2023
Accepted: 28 November 2023
First Online: 6 December 2023
Declarations
:
: The ethical approval to conduct the pilot survey, pre-test and main survey was granted by the Ethics Committee of China Pharmaceutical University (Project Number: CPU2019015). All methods of the study were carried out in accordance with the ethical standards of the Ethics Committee of China Pharmaceutical University and the principles of CFDA-GCP and the Helsinki Declaration. Written informed consent to participate was signed by all participated.
: Not applicable.
: The authors declare no competing interests.